Document Detail


Newer and upcoming therapies for melasma.
MedLine Citation:
PMID:  22772611     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Melasma is one of the most common and distressing pigmentary disorders presenting to dermatology clinics. The precise cause of melasma remains unknown; however, there are many possible contributing factors. It is notably difficult to treat and has a tendency to relapse. The existing and most tried topical therapy is hydroquinone and the triple combination with tretinoin and corticosteroids, which is considered the gold standard for melasma. Besides that, azelaic acid, kojic acid, arbutin, ascorbic acid, glycolic acid and salicylic peels have also been tried with limited success. However, multiple novel topical agents are being investigated for their potential as hypopigmenting agents with unique mode of action. But, further trials are required to study their efficacy and safety before they can be further recommended. The article highlights these newer formulations and also briefly mentions about the newer chemical peels and the much hyped lasers in treating this difficult and frustrating condition.
Authors:
Rashmi Sarkar; Shikha Chugh; Vijay K Garg
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Indian journal of dermatology, venereology and leprology     Volume:  78     ISSN:  0973-3922     ISO Abbreviation:  Indian J Dermatol Venereol Leprol     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7701852     Medline TA:  Indian J Dermatol Venereol Leprol     Country:  India    
Other Details:
Languages:  eng     Pagination:  417-28     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas.
Next Document:  Pediculosis capitis: An update.